Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH: A Longitudinal Multicentre Study
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Objective: Although the presymptomatic stages of frontotemporal dementia (FTD) provide a unique chance to delay or even prevent neurodegeneration by early intervention, they remain poorly defined. Leveraging a large multicenter cohort of genetic FTD mutation carriers, we provide a biomarker‐based stratification and biomarker cascade of the likely most treatment‐relevant stage within the presymptomatic phase: the conversion stage. Methods: We longitudinally assessed serum levels of neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH) in the Genetic FTD Initiative (GENFI) cohort (n = 444), using single‐molecule array technique. Subjects comprised 91 symptomatic and 179 presymptomatic subjects with mutations in the FTD genes C9orf72, GRN, or MAPT, and 174 mutation‐negative within‐family controls. Results: In a biomarker cascade, NfL increase preceded the hypothetical clinical onset by 15 years and concurred with brain atrophy onset, whereas pNfH increase started close to clinical onset. The conversion stage was marked by increased NfL, but still normal pNfH levels, while both were increased at the symptomatic stage. Intra‐individual change rates were increased for NfL at the conversion stage and for pNfH at the symptomatic stage, highlighting their respective potential as stage‐dependent dynamic biomarkers within the biomarker cascade. Increased NfL levels and NfL change rates allowed identification of presymptomatic subjects converting to symptomatic disease and capture of proximity‐to‐onset. We estimate stage‐dependent sample sizes for trials aiming to decrease neurofilament levels or change rates. Interpretation: Blood NfL and pNfH provide dynamic stage‐dependent stratification and, potentially, treatment response biomarkers in presymptomatic FTD, allowing demarcation of the conversion stage. The proposed biomarker cascade might pave the way towards a biomarker‐based precision medicine approach to genetic FTD. ANN NEUROL 2022;91:33–47
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Self-citationMutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988 · cited 2×
“Similarly, also pNfH blood levels might allow capturing neuronal disintegration and particularly axonal damage, possibly reflecting other features of the neurodegenerative process than NfL.(12,14) Leveraging a large multicenter cohort of genetic FTD mutation carriers, we here test the hypothesis that – in the biomarke…”
BackgroundSelf-citationCruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.-J., et al. (2006) · Nature · doi:10.1038/nature05017 · Cited by 1,512
Self-citationBridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the NFL Group, Alvarez-Cermeño, J. C., Andreasson, U., Axelsson, M., Bäckström, D. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1534 · Cited by 764
Kuhle, J., Barro, C., Andreasson, U., Derfuss, T., Lindberg, R., Sandelius, Å., Liman, V., Norgren, N., Blennow, K., & Zetterberg, H. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-1195 · Cited by 740
Self-citationKhalil, M., Pirpamer, L., Hofer, E., Voortman, M. M., Barro, C., Leppert, D., Benkert, P., Ropele, S., Enzinger, C., Fazekas, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14612-6 · Cited by 572
Self-citationA practical guide to immunoassay method validation
Andreasson, U., Perret-Liaudet, A., van Waalwijk van Doorn, L. J. C., Blennow, K., Chiasserini, D., Engelborghs, S., Fladby, T., Genc, S., Kruse, N., Kuiperij, H. B., et al. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00179 · Cited by 546
Rohrer, J. D., Nicholas, J. M., Cash, D. M., van Swieten, J., Dopper, E., Jiskoot, L., van Minkelen, R., Rombouts, S. A., Cardoso, M. J., Clegg, S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70324-2 · Cited by 538
Self-citationAn update on genetic frontotemporal dementia
Greaves, C. V., & Rohrer, J. D. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09363-4 · Cited by 500
Self-citationMoore, K. M., Nicholas, J., Grossman, M., McMillan, C. T., Irwin, D. J., Massimo, L., Van Deerlin, V. M., Warren, J. D., Fox, N. C., Rossor, M. N., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30394-1 · Cited by 313 · cited 1×
“Such fully biomarker-based stratification appears relevant as the age of onset in genetic FTD currently cannot be reliably predicted on the basis of the familial age of onset.(17,35) NfL might even quantitatively capture proximity-to-onset as individual NfL levels of converters continuously increased with proximity to…”
BackgroundSelf-citationBlood neurofilament light: a critical review of its application to neurologic disease
Barro, C., Chitnis, T., & Weiner, H. L. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51234 · Cited by 296 · cited 1×
“Thus, the combination of both biomarkers – NfL and pNfH – might be clinically relevant in the early and late stages of neurodegenerative diseases.(28) Although neurofilament increases are specific in that they signal axonal decay rate (rather than merely unspecific cell damage), their value in genetic FTD does not pri…”
BackgroundSelf-citationGendron, T. F., Chew, J., Stankowski, J. N., Hayes, L. R., Zhang, Y.-J., Prudencio, M., Carlomagno, Y., Daughrity, L. M., Jansen-West, K., Perkerson, E. A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai7866 · Cited by 265
van der Ende, E. L., Meeter, L. H., Poos, J. M., Panman, J. L., Jiskoot, L. C., Dopper, E. G. P., Papma, J. M., de Jong, F. J., Verberk, I. M. W., Teunissen, C., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30354-0 · Cited by 181 · cited 10×
“Thus, NfL and pNfH levels might provide disease stage-dependent stratification biomarkers and, possibly, treatment outcome biomarkers in genetic FTD.”
BackgroundMethodResultSelf-citationDevelopment of disease-modifying drugs for frontotemporal dementia spectrum disorders
Panza, F., Lozupone, M., Seripa, D., Daniele, A., Watling, M., Giannelli, G., & Imbimbo, B. P. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0330-x · Cited by 122 · cited 1×
“The presymptomatic stages of genetic FTD might provide a unique opportunity to delay or even prevent neurodegeneration by early therapeutic intervention, with promising targeted molecular therapies now entering clinical trials.(9,10) However, these presymptomatic stages – which encompass the accumulation of progressiv…”
BackgroundUse of the CDR® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium
Miyagawa, T., Brushaber, D., Syrjanen, J., Kremers, W., Fields, J., Forsberg, L. K., Heuer, H. W., Knopman, D., Kornak, J., Boxer, A., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.05.013 · Cited by 92
Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum
Wilke, C., Preische, O., Deuschle, C., Roeben, B., Apel, A., Barro, C., Maia, L., Maetzler, W., Kuhle, J., & Synofzik, M. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312972 · Cited by 79
Self-citationRosen, H. J., Boeve, B. F., & Boxer, A. L. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12004 · Cited by 55 · cited 1×
“Finally, our findings require validation in independent longitudinal genetic FTD cohorts, like the ALLFTD cohort.(43) In conclusion, our longitudinal study shows that blood NfL and pNfH provide stage-dependent stratification and, potentially, treatment response biomarkers in presymptomatic FTD, allowing demarcation of…”
Result
Cited by
Frontotemporal lobar degeneration
Grossman, M., Seeley, W. W., Boxer, A. L., Hillis, A. E., Knopman, D. S., Ljubenov, P. A., Miller, B., Piguet, O., Rademakers, R., Whitwell, J. L., et al. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00447-0 · Cited by 178
Self-citationGendron, T. F., Heckman, M. G., White, L. J., Veire, A. M., Pedraza, O., Burch, A. R., Bozoki, A. C., Dickerson, B. C., Domoto-Reilly, K., Foroud, T., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100607 · Cited by 70
Self-citationSheth, U., Öijerstedt, L., Heckman, M. G., White, L. J., Heuer, H. W., Lario Lago, A., Forsberg, L. K., Faber, K. M., Foroud, T. M., Rademakers, R., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00821-4 · Cited by 20
Self-citationThe role of neurofilament light in genetic frontotemporal lobar degeneration
Zetterberg, H., Teunissen, C., van Swieten, J., Kuhle, J., Boxer, A., Rohrer, J. D., Mitic, L., Nicholson, A. M., Pearlman, R., McCaughey, S. M., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac310 · Cited by 19
“Furthermore, higher baseline NfL correlated with worse longitudinal clinical measures and brain atrophy in all FTD genetic mutation types, arguing that blood-based NfL is predictive of short-term risk for FTD disease progression.(3,4,73,74) Longitudinal changes in plasma NfL in presymptomatic and symptomatic GRN and C…”
BackgroundMethodSelf-citation
Metadata
- Authors
- Wilke, C., Reich, S., van Swieten, J. C., Borroni, B., Sanchez‐Valle, R., Moreno, F., Laforce, R., Graff, C., Galimberti, D., Rowe, J. B., Masellis, M., Tartaglia, M. C., Finger, E., Vandenberghe, R., de Mendonça, A., Tagliavini, F., Santana, I., Ducharme, S., Butler, C. R., Gerhard, A., Levin, J., Danek, A., Otto, M., Frisoni, G., Ghidoni, R., Sorbi, S., Bocchetta, M., Todd, E., Kuhle, J., Barro, C., (GENFI), G. F. D. I., Rohrer, J. D., & Synofzik, M.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2021-11-29
- Volume
- 91
- Issue
- 1
- Pages
- 33-47
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W3212709990
- Cited by
- 46
- References
- 19
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.